This therapeutic concept proposes a multi-modal prevention bundle designed for individuals with genetic risk factors for neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia) (APOE4, LRRK2, GBA, SNCA, C9orf72, MAPT, FUS). Unlike single-drug approaches, this package combines targeted pharmacological interventions, lifestyle modifications, and biomarker-guided monitoring to delay or prevent clinical onset in prodromal stages.[@reitz2021]
This therapeutic concept proposes a multi-modal prevention bundle designed for individuals with genetic risk factors for neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia) (APOE4, LRRK2, GBA, SNCA, C9orf72, MAPT, FUS). Unlike single-drug approaches, this package combines targeted pharmacological interventions, lifestyle modifications, and biomarker-guided monitoring to delay or prevent clinical onset in prodromal stages.[@reitz2021]
| Dimension | Specification |
|-----------|---------------|
| Modality | Multi-component therapeutic bundle (pharma + lifestyle) |
| Delivery | Centralized memory clinic with genetic counseling |
| Selectivity | Genotype-specific drug selection based on risk allele |
| Duration | Lifelong intervention with quarterly monitoring |
| Indication | Preclinical Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia in genetically at-risk individuals |
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Novel combination approach; individual components exist but package is innovative |
| Mechanistic Rationale | 8 | Strong scientific basis for each component; synergy is biologically plausible |
| Addresses Root Cause | 7 | Addresses multiple pathways simultaneously; prevention rather than treatment |
| Delivery Feasibility | 8 | Uses existing interventions; delivery through memory clinics is established |
| Safety Plausibility | 8 | Components have known safety profiles; combination can be managed |
| Combinability | 9 | Highly combinable; designed as a bundle approach |
| Biomarker Availability | 8 | Blood biomarkers (p-tau217, NfL) enable tracking; PET for amyloid/tau |
| De-risking Path | 7 | Each component can be tested independently; adaptive trial design possible |
| Multi-disease Potential | 9 | Applicable to AD, PD, ALS, FTD based on specific genetic risks |
| Patient Impact | 8 | Prevention is better than treatment; high impact if successful |
Total: 71/100
| Milestone | Duration | Estimated Cost | Key Activities |
|-----------|----------|----------------|----------------|
| Genetic cohort establishment | 3 months | $200,000 | Partner with genetic testing companies (23andMe, AncestryDNA) for anonymized carrier identification; establish recruitment protocols |
| Clinic network setup | 3 months | $150,000 | Train 10 memory clinics on genetic counseling and protocol delivery; develop standardized assessment workflows |
| Baseline biomarker protocol | 3 months | $100,000 | Establish p-tau217, NfL, and PET imaging protocols; validate assay performance across sites |
| Lifestyle intervention development | 6 months | $180,000 | Design exercise, diet, and sleep optimization protocols; develop patient-facing materials |
Phase 1 Total: ~$630,000
| Component | Estimated Cost | Description |
|-----------|----------------|-------------|
| Site expansion (25 clinics) | $300,000 | Site initiation, IRB approvals, staff training |
| Participant enrollment | $400,000 | 200 participants with genetic risk (APOE4/4, LRRK2 G2019S, GBA carriers) |
| 12-month intervention | $600,000 | Multi-modal therapy delivery, biomarker monitoring |
| Safety monitoring | $150,000 | Adverse event tracking, DSMB oversight |
| Biomarker analysis | $200,000 | Longitudinal p-tau217, NfL, PET imaging |
Phase 2a Total: ~$1,650,000
| Component | Estimated Cost | Description |
|-----------|----------------|-------------|
| Expanded enrollment | $800,000 | 500 additional at-risk participants across diverse backgrounds |
| Randomized design | $500,000 | Compare full bundle vs. lifestyle-only vs. standard care |
| Biomarker endpoints | $400,000 | p-tau217 trajectory, NfL change, PET amyloid/tau quantitation |
| Cognitive endpoints | $250,000 | Comprehensive neuropsychological battery |
| Data analytics | $200,000 | Machine learning models for responder identification |
Phase 2b Total: ~$2,150,000
| Component | Estimated Cost | Description |
|-----------|----------------|-------------|
| Global site network (50 sites) | $1,500,000 | Site initiation across US, EU, Asia |
| Participant enrollment | $2,500,000 | 2,000 genetically at-risk individuals |
| 24-month treatment period | $4,000,000 | Full bundle delivery, comprehensive monitoring |
| Primary endpoint analysis | $500,000 | Time to clinical conversion, biomarker progression |
| Regulatory interactions | $300,000 | Breakthrough therapy designation, accelerated approval pathway |
Phase 3 Total: ~$8,800,000
| Phase | Duration | Cost |
|-------|----------|------|
| Phase 1 | 12 months | $630,000 |
| Phase 2a | 12 months | $1,650,000 |
| Phase 2b | 18 months | $2,150,000 |
| Phase 3 | 24 months | $8,800,000 |
| Total | 66 months | $13,230,000 |
| Scenario | Probability | Adjusted Cost | Key Assumptions |
|----------|-------------|---------------|-----------------|
| Base case | 50% | $13.2M | Standard development path |
| Fast path | 25% | $16M | Breakthrough designation, 6-month acceleration |
| Slow path | 25% | $18M | Additional Phase 2, regulatory delays |
| Gate | Timing | Go/No-Go Criteria |
|------|--------|-------------------|
| Phase 1 → Phase 2 | Month 12 | ≥80% participant retention, no unexpected safety signals |
| Phase 2a → Phase 2b | Month 24 | Biomarker trend in expected direction (p-tau217 <10% increase) |
| Phase 2b → Phase 3 | Month 42 | Clinically meaningful slowing of biomarker progression |
| Phase 3 → Filing | Month 66 | Primary endpoint met (time to conversion HR <0.7) |